{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,31]],"date-time":"2026-10-31T02:21:49Z","timestamp":1793413309049,"version":"4.5.0"},"reference-count":99,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,7,28]],"date-time":"2026-07-28T00:00:00Z","timestamp":1785196800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:p>\n                    Anti-MuSK antibody\u2013positive myasthenia gravis (MuSK-MG) is characterized by severe and potentially life-threatening weakness. Anti-MuSK antibodies are key pathogenic drivers of this disorder. This review provides a comprehensive summary of the current state-of-the-art with respect to the understanding of MuSK and its role in MuSK-MG. MuSK, a receptor tyrosine kinase, is essential at the neuromuscular junction, where it forms an agrin\u2013LRP4\u2013MuSK tripartite functional complex that initiates and maintains agrin-induced acetylcholine receptor clustering at the postsynaptic membrane. Although anti-MuSK antibodies encompass all IgG subclasses (IgG1\u20134), IgG4 is the predominant pathogenic subclass.\n                    <jats:italic>In vivo<\/jats:italic>\n                    , IgG4 antibodies undergo Fab-arm exchange, acquiring functional monovalency; this monovalent IgG4 disrupts LRP4\u2013MuSK interactions, thereby blocking downstream signaling and precipitating myasthenic symptoms. Emerging evidence indicates that IgG1\u20133 anti-MuSK antibodies are also pathogenic, although some clones exhibit agonistic effects on MuSK phosphorylation. Further, this review examines the various diagnostic methods for this condition and weighs the advantages and disadvantages. Both MuSK protein and its autoantibodies are pivotal for diagnosis and therapy. Radioimmunoprecipitation assays and enzyme-linked immunosorbent assays and their benefits ad limitations are discussed, and cell-based assays are noted for their high accuracy. Anti-MuSK antibody testing is the gold standard diagnostic biomarker. Finally, the review covers the various therapeutic strategies for MuSK-MG, including immunosuppressants, monoclonal antibodies, CAR-T cell therapy, and neonatal Fc receptor blockade. B-cell\u2013targeted therapies (e.g., anti-CD20 monoclonal antibodies) and MuSK agonists represent promising future therapeutic strategies for MuSK-MG. Overall, this review provides a definitive summary of the present practices and future strategies for the diagnosis and treatment of MuSK-MG, laying out clear markers for further studies that have to be undertaken to enhance our understanding of this condition.\n                  <\/jats:p>","DOI":"10.3389\/fimmu.2026.1732705","type":"journal-article","created":{"date-parts":[[2026,7,28]],"date-time":"2026-07-28T10:15:15Z","timestamp":1785233715000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":1,"title":["MuSK myasthenia gravis: from antigen\u2013antibody to clinical translation"],"prefix":"10.3389","volume":"17","author":[{"given":"Xinyue","family":"Zhou","sequence":"first","affiliation":[{"name":"Department of Neuroimmunology, Henan Institute of Medical and Pharmaceutical Sciences, Zhengzhou University","place":["Zhengzhou, Henan, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Neuroimmunology, Henan Institute of Medical and Pharmaceutical Sciences, Zhengzhou University","place":["Zhengzhou, Henan, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haiyan","family":"Dong","sequence":"additional","affiliation":[{"name":"Department of Neuroimmunology, Henan Institute of Medical and Pharmaceutical Sciences, Zhengzhou University","place":["Zhengzhou, Henan, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xinxin","family":"Cui","sequence":"additional","affiliation":[{"name":"Department of Neuroimmunology, Henan Institute of Medical and Pharmaceutical Sciences, Zhengzhou University","place":["Zhengzhou, Henan, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hanxin","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Neuroimmunology, Henan Institute of Medical and Pharmaceutical Sciences, Zhengzhou University","place":["Zhengzhou, Henan, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mengdi","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Neuroimmunology, Henan Institute of Medical and Pharmaceutical Sciences, Zhengzhou University","place":["Zhengzhou, Henan, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruichen","family":"Liu","sequence":"additional","affiliation":[{"name":"Department of Neuroimmunology, Henan Institute of Medical and Pharmaceutical Sciences, Zhengzhou University","place":["Zhengzhou, Henan, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qian","family":"Liu","sequence":"additional","affiliation":[{"name":"Department of Neuroimmunology, Henan Institute of Medical and Pharmaceutical Sciences, Zhengzhou University","place":["Zhengzhou, Henan, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jia","family":"Hu","sequence":"additional","affiliation":[{"name":"Department of Neuroimmunology, Henan Institute of Medical and Pharmaceutical Sciences, Zhengzhou University","place":["Zhengzhou, Henan, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing","family":"Liu","sequence":"additional","affiliation":[{"name":"Department of Neuroimmunology, Henan Institute of Medical and Pharmaceutical Sciences, Zhengzhou University","place":["Zhengzhou, Henan, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yingna","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Neuroimmunology, Henan Institute of Medical and Pharmaceutical Sciences, Zhengzhou University","place":["Zhengzhou, Henan, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xue","family":"Zhao","sequence":"additional","affiliation":[{"name":"Department of Neuroimmunology, Henan Institute of Medical and Pharmaceutical Sciences, Zhengzhou University","place":["Zhengzhou, Henan, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ting","family":"Chang","sequence":"additional","affiliation":[{"name":"Department of Neurology, Tangdu Hospital, The Fourth Military Medical University","place":["Xi\u2019an, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhe","family":"Ruan","sequence":"additional","affiliation":[{"name":"Department of Neurology, Tangdu Hospital, The Fourth Military Medical University","place":["Xi\u2019an, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junhong","family":"Yang","sequence":"additional","affiliation":[{"name":"Department of Encephalopathy, First Affiliated Hospital of Henan University of Chinese Medicine","place":["Zhengzhou, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jie","family":"Lv","sequence":"additional","affiliation":[{"name":"Department of Neuroimmunology, Henan Institute of Medical and Pharmaceutical Sciences, Zhengzhou University","place":["Zhengzhou, Henan, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Feng","family":"Gao","sequence":"additional","affiliation":[{"name":"Department of Neuroimmunology, Henan Institute of Medical and Pharmaceutical Sciences, Zhengzhou University","place":["Zhengzhou, Henan, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,7,28]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1038\/2071097a0","article-title":"Release of acetylcholine from a nerve terminal by electric pulses of variable strength and duration","volume":"207","author":"Katz","year":"1965","journal-title":"Nature"},{"key":"B2","doi-asserted-by":"publisher","first-page":"487","DOI":"10.1016\/s0006-8993(99)01067-7","article-title":"Multiple types of spontaneous excitatory synaptic currents in salamander retinal ganglion cells","volume":"821","author":"Gao","year":"1999","journal-title":"Brain Res"},{"key":"B3","article-title":"Structure and function of neuromuscular junctions in the vastus lateralis of man. A motor point biopsy study of two groups of patients","volume":"115","author":"Slater","year":"1992","journal-title":"Brain"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.3390\/cells8070671","article-title":"Myasthenia gravis: pathogenic effects of autoantibodies on neuromuscular architecture","volume":"8","author":"Koneczny","year":"2019","journal-title":"Cells"},{"key":"B5","doi-asserted-by":"publisher","first-page":"47","DOI":"10.11477\/mf.1416202557","article-title":"Pathogenesis of musk antibody-positive myasthenia gravis","volume":"76","author":"Shigemoto","year":"2024","journal-title":"Brain Nerve"},{"key":"B6","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1002\/mus.22006","article-title":"Anti-musk antibody myasthenia gravis: clinical findings and response to treatment in two large cohorts","volume":"44","author":"Guptill","year":"2011","journal-title":"Muscle Nerve"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1016\/s1474-4422(15)00145-3","article-title":"Myasthenia gravis: subgroup classification and therapeutic strategies","volume":"14","author":"Gilhus","year":"2015","journal-title":"Lancet Neurol"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2020.00707","article-title":"Muscle-specific kinase myasthenia gravis","volume":"11","author":"Borges","year":"2020","journal-title":"Front Immunol"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1038\/85520","article-title":"Auto-antibodies to the receptor tyrosine kinase musk in patients with myasthenia gravis without acetylcholine receptor antibodies","volume":"7","author":"Hoch","year":"2001","journal-title":"Nat Med"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.4103\/ant.Ant_112_0081","article-title":"Clinical features and outcome in myasthenia gravis patients with antimuscle-specific tyrosine kinase antibody: a retrospective study","volume":"34","author":"Chung","year":"2025","journal-title":"Acta Neurol Taiwan"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1083\/jcb.150.6.1321","article-title":"The actin-driven movement and formation of acetylcholine receptor clusters","volume":"150","author":"Dai","year":"2000","journal-title":"J Cell Biol"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.2300453120","article-title":"Structural insights into the assembly of the agrin\/Lrp4\/musk signaling complex","volume":"120","author":"Xie","year":"2023","journal-title":"Proc Natl Acad Sci USA"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1313944110","article-title":"Musk igg4 autoantibodies cause myasthenia gravis by inhibiting binding between musk and lrp4","volume":"110","author":"Huijbers","year":"2013","journal-title":"Proc Natl Acad Sci USA"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1212\/nxi.0000000000000547","article-title":"Musk myasthenia gravis monoclonal antibodies: valency dictates pathogenicity","volume":"6","author":"Huijbers","year":"2019","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1172\/jci66039","article-title":"Antibodies against low-density lipoprotein receptor-related protein 4 induce myasthenia gravis","volume":"123","author":"Shen","year":"2013","journal-title":"J Clin Invest"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1172\/jci29894","article-title":"Myasthenia gravis: past, present, and future","volume":"116","author":"Conti-Fine","year":"2006","journal-title":"J Clin Invest"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2018.00097","article-title":"A new classification system for igg4 autoantibodies","volume":"9","author":"Koneczny","year":"2018","journal-title":"Front Immunol"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1101\/cshperspect.a009167","article-title":"The role of musk in synapse formation and neuromuscular disease","volume":"5","author":"Burden","year":"2013","journal-title":"Cold Spring Harb Perspect Biol"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1093\/brain\/aws025","article-title":"Muscle-specific kinase myasthenia gravis igg4 autoantibodies cause severe neuromuscular junction dysfunction in mice","volume":"135","author":"Klooster","year":"2012","journal-title":"Brain"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1111\/nyas.13518","article-title":"Myasthenia gravis with antibodies to musk: an update","volume":"1412","author":"Evoli","year":"2018","journal-title":"Ann N Y Acad Sci"},{"key":"B21","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1038\/s41572-019-0079-y","article-title":"Myasthenia gravis","volume":"5","author":"Gilhus","year":"2019","journal-title":"Nat Rev Dis Primers"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1002\/mus.26404","article-title":"Thymectomy may not be associated with clinical improvement in musk myasthenia gravis","volume":"59","author":"Clifford","year":"2019","journal-title":"Muscle Nerve"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1093\/brain\/awg223","article-title":"Clinical correlates with anti-musk antibodies in generalized seronegative myasthenia gravis","volume":"126","author":"Evoli","year":"2003","journal-title":"Brain"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0b013e3182407982","article-title":"Long-lasting treatment effect of rituximab in musk myasthenia","volume":"78","author":"D\u00edaz-Manera","year":"2012","journal-title":"Neurology"},{"key":"B25","doi-asserted-by":"publisher","first-page":"699","DOI":"10.1007\/s00415-019-09191-6","article-title":"High efficacy of rituximab for myasthenia gravis: a comprehensive nationwide study in Austria","volume":"266","author":"Topakian","year":"2019","journal-title":"J Neurol"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1212\/wnl.0000000000004341","article-title":"Rituximab as treatment for anti-musk myasthenia gravis: multicenter blinded prospective review","volume":"89","author":"Hehir","year":"2017","journal-title":"Neurology"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1136\/jnnp-2019-322606","article-title":"Rituximab in achr subtype of myasthenia gravis: systematic review","volume":"91","author":"Di Stefano","year":"2020","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1212\/wnl.0000000000011124","article-title":"International consensus guidance for management of myasthenia gravis: 2020 update","volume":"96","author":"Narayanaswami","year":"2021","journal-title":"Neurology"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.90.7.2895","article-title":"Muscle-specific trk-related receptor with a kringle domain defines a distinct class of receptor tyrosine kinases","volume":"90","author":"Jennings","year":"1993","journal-title":"Proc Natl Acad Sci USA"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbapap.2013.02.034","article-title":"Structure and activation of musk, a receptor tyrosine kinase central to neuromuscular junction formation","volume":"1834","author":"Hubbard","year":"2013","journal-title":"Biochim Biophys Acta"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1016\/j.jmb.2006.09.019","article-title":"Crystal structure of the agrin-responsive immunoglobulin-like domains 1 and 2 of the receptor tyrosine kinase musk","volume":"364","author":"Stiegler","year":"2006","journal-title":"J Mol Biol"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1016\/s0092-8674(00)81252-0","article-title":"Agrin acts via a musk receptor complex","volume":"85","author":"Glass","year":"1996","journal-title":"Cell"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.080061997","article-title":"The in vitro and in vivo phosphotyrosine map of activated musk","volume":"97","author":"Watty","year":"2000","journal-title":"Proc Natl Acad Sci USA"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M111.279307","article-title":"Agrin binds to the n-terminal region of lrp4 protein and stimulates association between lrp4 and the first immunoglobulin-like domain in muscle-specific kinase (musk)","volume":"286","author":"Zhang","year":"2011","journal-title":"J Biol Chem"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1101\/gad.180885.111","article-title":"Structural basis of agrin-lrp4-musk signaling","volume":"26","author":"Zong","year":"2012","journal-title":"Genes Dev"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1212\/01.wnl.0000228225.23349.5d","article-title":"Anti-musk antibodies: correlation with myasthenia gravis severity","volume":"67","author":"Bartoccioni","year":"2006","journal-title":"Neurology"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1016\/j.jneuroim.2008.01.013","article-title":"Clinical fluctuations in musk myasthenia gravis are related to antigen-specific igg4 instead of igg1","volume":"195","author":"Niks","year":"2008","journal-title":"J Neuroimmunol"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1016\/j.jneuroim.2015.12.016","article-title":"Longitudinal epitope mapping in musk myasthenia gravis: implications for disease severity","volume":"291","author":"Huijbers","year":"2016","journal-title":"J Neuroimmunol"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1523\/jneurosci.1279-23.2025","article-title":"Musk regulates neuromuscular junction nav1.4 localization and excitability","volume":"45","author":"Fish","year":"2025","journal-title":"J Neurosci"},{"key":"B40","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1186\/s10020-019-0129-7","article-title":"Disorders of fz-crd; insights towards fz-crd folding and therapeutic landscape","volume":"26","author":"Milhem","year":"2019","journal-title":"Mol Med"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1007\/s00018-012-1209-9","article-title":"Structural mechanisms of the agrin-lrp4-musk signaling pathway in neuromuscular junction differentiation","volume":"70","author":"Zong","year":"2013","journal-title":"Cell Mol Life Sci"},{"key":"B42","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.jmb.2009.07.091","article-title":"Crystal structure of the frizzled-like cysteine-rich domain of the receptor tyrosine kinase musk","volume":"393","author":"Stiegler","year":"2009","journal-title":"J Mol Biol"},{"key":"B43","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1038\/35083601","article-title":"Insights into wnt binding and signalling from the structures of two frizzled cysteine-rich domains","volume":"412","author":"Dann","year":"2001","journal-title":"Nature"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.1172\/jci173308","article-title":"Musk cysteine-rich domain antibodies are pathogenic in a mouse model of autoimmune myasthenia gravis","volume":"135","author":"Halliez","year":"2025","journal-title":"J Clin Invest"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.1002\/humu.23949","article-title":"Congenital myasthenic syndrome due to mutations in musk suggests that the level of musk phosphorylation is crucial for governing synaptic structure","volume":"41","author":"Rodr\u00edguez Cruz","year":"2020","journal-title":"Hum Mutat"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.1093\/hmg\/ddh333","article-title":"Musk, a new target for mutations causing congenital myasthenic syndrome","volume":"13","author":"Chevessier","year":"2004","journal-title":"Hum Mol Genet"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.1093\/hmg\/ddq110","article-title":"Mutations in musk causing congenital myasthenic syndrome impair musk-dok-7 interaction","volume":"19","author":"Maselli","year":"2010","journal-title":"Hum Mol Genet"},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.1002\/mus.25973","article-title":"B cells in the pathophysiology of myasthenia gravis","volume":"57","author":"Yi","year":"2018","journal-title":"Muscle Nerve"},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.ado7189","article-title":"Argx-119 is an agonist antibody for human musk that reverses disease relapse in a mouse model of congenital myasthenic syndrome","volume":"16","author":"Vanhauwaert","year":"2024","journal-title":"Sci Transl Med"},{"key":"B50","doi-asserted-by":"publisher","DOI":"10.1002\/ana.20061","article-title":"Detection and characterization of musk antibodies in seronegative myasthenia gravis","volume":"55","author":"McConville","year":"2004","journal-title":"Ann Neurol"},{"key":"B51","doi-asserted-by":"publisher","DOI":"10.1212\/nxi.0000000000200147","article-title":"Igg1-3 musk antibodies inhibit achr cluster formation, restored by shp2 inhibitor, despite normal musk, dok7, or achr subunit phosphorylation","volume":"10","author":"Cao","year":"2023","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"key":"B52","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.834342","article-title":"Igg4 autoantibodies in organ-specific autoimmunopathies: reviewing class switching, antibody-producing cells, and specific immunotherapies","volume":"13","author":"Koneczny","year":"2022","journal-title":"Front Immunol"},{"key":"B53","doi-asserted-by":"publisher","DOI":"10.1126\/science.1144603","article-title":"Anti-inflammatory activity of human igg4 antibodies by dynamic fab arm exchange","volume":"317","author":"van der Neut Kolfschoten","year":"2007","journal-title":"Science"},{"key":"B54","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaut.2016.11.005","article-title":"Igg4 autoantibodies against muscle-specific kinase undergo fab-arm exchange in myasthenia gravis patients","volume":"77","author":"Koneczny","year":"2017","journal-title":"J Autoimmun"},{"key":"B55","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0080695","article-title":"Musk myasthenia gravis igg4 disrupts the interaction of lrp4 with musk but both igg4 and igg1-3 can disperse preformed agrin-independent achr clusters","volume":"8","author":"Koneczny","year":"2013","journal-title":"PloS One"},{"key":"B56","doi-asserted-by":"publisher","DOI":"10.1038\/s41577-023-00871-z","article-title":"The unique properties of igg4 and its roles in health and disease","volume":"23","author":"Rispens","year":"2023","journal-title":"Nat Rev Immunol"},{"key":"B57","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1087532","article-title":"Factors affecting igg4-mediated complement activation","volume":"14","author":"Oskam","year":"2023","journal-title":"Front Immunol"},{"key":"B58","doi-asserted-by":"publisher","DOI":"10.1113\/jphysiol.2010.190298","article-title":"Patient autoantibodies deplete postsynaptic muscle-specific kinase leading to disassembly of the ach receptor scaffold and myasthenia gravis in mice","volume":"588","author":"Cole","year":"2010","journal-title":"J Physiol"},{"key":"B59","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2014.00520","article-title":"Igg subclasses and allotypes: from structure to effector functions","volume":"5","author":"Vidarsson","year":"2014","journal-title":"Front Immunol"},{"key":"B60","doi-asserted-by":"publisher","DOI":"10.1172\/jci.insight.127167","article-title":"Characterization of pathogenic monoclonal autoantibodies derived from muscle-specific kinase myasthenia gravis patients","volume":"4","author":"Takata","year":"2019","journal-title":"JCI Insight"},{"key":"B61","doi-asserted-by":"publisher","DOI":"10.1093\/brain\/awaf410","article-title":"Iga autoantibodies demonstrate a novel mechanism of musk myasthenia gravis pathology","volume":"149","author":"Masi","year":"2026","journal-title":"Brain"},{"key":"B62","doi-asserted-by":"publisher","DOI":"10.7554\/eLife.34375","article-title":"Preserving neuromuscular synapses in als by stimulating musk with a therapeutic agonist antibody","volume":"7","author":"Cantor","year":"2018","journal-title":"Elife"},{"key":"B63","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1016\/j.drudis.2021.09.008","article-title":"Agonist antibody discovery: experimental, computational, and rational engineering approaches","volume":"27","author":"Schardt","year":"2022","journal-title":"Drug Discov Today"},{"key":"B64","doi-asserted-by":"publisher","DOI":"10.1093\/braincomms\/fcag115","article-title":"Gene-specific response to muscle specific kinase agonist antibody in the treatment of congenital myasthenic syndromes","volume":"8","author":"Ho","year":"2026","journal-title":"Brain Commun"},{"key":"B65","doi-asserted-by":"publisher","first-page":"7478","DOI":"10.1038\/s41598-023-32641-1","article-title":"Development and characterization of agonistic antibodies targeting the ig-like 1 domain of musk","volume":"13","author":"Lim","year":"2023","journal-title":"Sci Rep"},{"key":"B66","doi-asserted-by":"publisher","DOI":"10.1016\/j.isci.2024.111684","article-title":"Patient-specific therapeutic benefit of musk agonist antibody argx-119 in musk myasthenia gravis passive transfer models","volume":"28","author":"Lim","year":"2025","journal-title":"iScience"},{"key":"B67","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.2408324121","article-title":"Agonist antibody to musk protects mice from musk myasthenia gravis","volume":"121","author":"Oury","year":"2024","journal-title":"Proc Natl Acad Sci USA"},{"key":"B68","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3969\/j.issn.1006-2963.2021.01.001","article-title":"Chinese guidelines for diagnosis and treatment of myasthenia gravis (2020 edition)","volume":"28","author":"Chang","year":"2021","journal-title":"Chinese Journal of Neuroimmunology and Neurology"},{"key":"B69","doi-asserted-by":"publisher","DOI":"10.1016\/j.jneuroim.2019.577076","article-title":"A novel musk cell-based myasthenia gravis diagnostic assay","volume":"337","author":"Han","year":"2019","journal-title":"J Neuroimmunol"},{"key":"B70","doi-asserted-by":"publisher","DOI":"10.1111\/ene.70123","article-title":"Testing for acetylcholine receptor and muscle-specific tyrosine kinase antibodies by fixed cell-based assay in clinical practice: positive predictive value for myasthenia gravis","volume":"32","author":"Li","year":"2025","journal-title":"Eur J Neurol"},{"key":"B71","doi-asserted-by":"publisher","DOI":"10.1007\/s00415-022-11458-4","article-title":"Clinical pitfalls and serological diagnostics of musk myasthenia gravis","volume":"270","author":"Kwon","year":"2023","journal-title":"J Neurol"},{"key":"B72","doi-asserted-by":"publisher","DOI":"10.1007\/s00415-024-12317-0","article-title":"Inter-laboratory comparison of routine autoantibody detection methods for autoimmune neuropathies and myasthenia gravis","volume":"271","author":"Mart\u00ednez-Mart\u00ednez","year":"2024","journal-title":"J Neurol"},{"key":"B73","doi-asserted-by":"publisher","DOI":"10.1212\/nxi.0000000000200038","article-title":"Comparison of fixed and live cell-based assay for the detection of achr and musk antibodies in myasthenia gravis","volume":"10","author":"Spagni","year":"2023","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"key":"B74","doi-asserted-by":"publisher","DOI":"10.1007\/s00415-026-13810-4","article-title":"Enhanced antibody detection via live cell-based assay among ria negative myasthenia gravis patients: toward improved diagnosis and clinical correlates","volume":"273","author":"Rinaldi","year":"2026","journal-title":"J Neurol"},{"key":"B75","doi-asserted-by":"publisher","DOI":"10.1016\/j.jns.2025.123449","article-title":"Prevalence and course of muscle-specific receptor tyrosine kinase (musk) antibodies in myasthenia gravis - a retrospective study","volume":"472","author":"Stahl","year":"2025","journal-title":"J Neurol Sci"},{"key":"B76","doi-asserted-by":"publisher","DOI":"10.1093\/brain\/awn092","article-title":"Igg1 antibodies to acetylcholine receptors in 'seronegative' myasthenia gravis","volume":"131","author":"Leite","year":"2008","journal-title":"Brain"},{"key":"B77","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1016\/j.expneurol.2015.01.011","article-title":"Use of cell-based assays in myasthenia gravis and other antibody-mediated diseases","volume":"270","author":"Rodriguez Cruz","year":"2015","journal-title":"Exp Neurol"},{"key":"B78","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1016\/s1474-4422(21)00463-4","article-title":"Advances and ongoing research in the treatment of autoimmune neuromuscular junction disorders","volume":"21","author":"Verschuuren","year":"2022","journal-title":"Lancet Neurol"},{"key":"B79","doi-asserted-by":"publisher","DOI":"10.3389\/fneur.2020.00660","article-title":"Musk-associated myasthenia gravis: clinical features and management","volume":"11","author":"Rodolico","year":"2020","journal-title":"Front Neurol"},{"key":"B80","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1007\/s40259-024-00701-1","article-title":"New and emerging biological therapies for myasthenia gravis: a focussed review for clinical decision-making","volume":"39","author":"Gerischer","year":"2025","journal-title":"BioDrugs"},{"key":"B81","doi-asserted-by":"publisher","DOI":"10.2147\/itt.S492062","article-title":"Advances in b cell targeting for treating muscle-specific tyrosine kinase-associated myasthenia gravis","volume":"13","author":"Hu","year":"2024","journal-title":"Immunotargets Ther"},{"key":"B82","doi-asserted-by":"publisher","DOI":"10.1038\/sj.onc.1206939","article-title":"Rituximab (monoclonal anti-cd20 antibody): mechanisms of action and resistance","volume":"22","author":"Smith","year":"2003","journal-title":"Oncogene"},{"key":"B83","doi-asserted-by":"publisher","first-page":"S3","DOI":"10.1097\/00001813-200211002-00002","article-title":"Mechanism of action of rituximab","author":"Cerny","year":"2002","journal-title":"Anticancer Drugs"},{"key":"B84","doi-asserted-by":"publisher","DOI":"10.1186\/ar3908","article-title":"B-cell subpopulations in humans and their differential susceptibility to depletion with anti-cd20 monoclonal antibodies","author":"Leandro","year":"2013","journal-title":"Arthritis Res Ther"},{"key":"B85","doi-asserted-by":"publisher","DOI":"10.1007\/s11845-024-03763-w","article-title":"Clinical and laboratory remission with rituximab in anti-musk-positive myasthenia gravis","volume":"193","author":"Inan","year":"2024","journal-title":"Ir J Med Sci"},{"key":"B86","doi-asserted-by":"publisher","DOI":"10.1016\/j.coi.2019.09.004","article-title":"B cell targeted therapies in autoimmune disease","volume":"61","author":"Barnas","year":"2019","journal-title":"Curr Opin Immunol"},{"key":"B87","doi-asserted-by":"publisher","DOI":"10.1016\/j.autrev.2020.102736","article-title":"B cell activating factor (baff): structure, functions, autoimmunity and clinical implications in systemic lupus erythematosus (sle)","volume":"20","author":"M\u00f6ckel","year":"2021","journal-title":"Autoimmun Rev"},{"key":"B88","doi-asserted-by":"publisher","DOI":"10.1212\/wnl.0000000000005323","article-title":"Randomized study of adjunctive belimumab in participants with generalized myasthenia gravis","volume":"90","author":"Hewett","year":"2018","journal-title":"Neurology"},{"key":"B89","doi-asserted-by":"publisher","DOI":"10.3390\/cells13060556","article-title":"Musk myasthenia gravis-potential pathomechanisms and treatment directed against specific targets","volume":"13","author":"Dziadkowiak","year":"2024","journal-title":"Cells"},{"key":"B90","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2024.1465191","article-title":"Application of novel car technologies to improve treatment of autoimmune disease","volume":"15","author":"Cheever","year":"2024","journal-title":"Front Immunol"},{"key":"B91","doi-asserted-by":"publisher","DOI":"10.1038\/s44321-024-00043-z","article-title":"B cell lineage reconstitution underlies car-t cell therapeutic efficacy in patients with refractory myasthenia gravis","volume":"16","author":"Tian","year":"2024","journal-title":"EMBO Mol Med"},{"key":"B92","doi-asserted-by":"publisher","first-page":"1923","DOI":"10.1038\/s41587-024-02502-x","article-title":"Author correction: precision targeting of autoantigen-specific b cells in muscle-specific tyrosine kinase myasthenia gravis with chimeric autoantibody receptor t cells","volume":"42","author":"Oh","year":"2024","journal-title":"Nat Biotechnol"},{"key":"B93","doi-asserted-by":"publisher","DOI":"10.1126\/sciadv.aax9586","article-title":"Blocking fcrn in humans reduces circulating igg levels and inhibits igg immune complex-mediated immune responses","volume":"5","author":"Blumberg","year":"2019","journal-title":"Sci Adv"},{"key":"B94","doi-asserted-by":"publisher","DOI":"10.1080\/19420862.2018.1505464","article-title":"Generation and characterization of a high affinity anti-human fcrn antibody, rozanolixizumab, and the effects of different molecular formats on the reduction of plasma igg concentration","volume":"10","author":"Smith","year":"2018","journal-title":"MAbs"},{"key":"B95","doi-asserted-by":"publisher","DOI":"10.1007\/s40120-025-00748-4","article-title":"Real-world experience with fcrn inhibitors efgartigimod and rozanolixizumab in myasthenia gravis: administration in multiple cycles and transition from intravenous to subcutaneous formulation","volume":"14","author":"Yoshikawa","year":"2025","journal-title":"Neurol Ther"},{"key":"B96","doi-asserted-by":"publisher","DOI":"10.3389\/fneur.2024.1486659","article-title":"Efgartigimod treatment in patients with anti-musk-positive myasthenia gravis in exacerbation","volume":"15","author":"Shi","year":"2024","journal-title":"Front Neurol"},{"key":"B97","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD014574.pub2","article-title":"Rituximab for myasthenia gravis","volume":"7","author":"Dodd","year":"2025","journal-title":"Cochrane Database Syst Rev"},{"key":"B98","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2024.1404191","article-title":"Targeting autoimmune mechanisms by precision medicine in myasthenia gravis","volume":"15","author":"Cavalcante","year":"2024","journal-title":"Front Immunol"},{"key":"B99","doi-asserted-by":"publisher","DOI":"10.4103\/1673-5374.363824","article-title":"Fcrn inhibitors: a novel option for the treatment of myasthenia gravis","volume":"18","author":"Zhu","year":"2023","journal-title":"Neural Regener Res"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1732705\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,28]],"date-time":"2026-07-28T10:15:18Z","timestamp":1785233718000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1732705\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,28]]},"references-count":99,"alternative-id":["10.3389\/fimmu.2026.1732705"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2026.1732705","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,28]]},"article-number":"1732705"}}